{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:46:31Z","timestamp":1794264391594,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013297","name":"EC | Eurostars","doi-asserted-by":"publisher","award":["E!9036"],"award-info":[{"award-number":["E!9036"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function and improved patient survival. For this purpose, we developed the selective anti-ATTR antibody NI301A, a recombinant human monoclonal immunoglobulin G1. NI301A was cloned following comprehensive analyses of memory B cell repertoires derived from healthy elderly subjects. NI301A binds selectively with high affinity to the disease-associated ATTR aggregates of either wild-type or variant ATTR related to sporadic or hereditary disease, respectively. It does not bind physiological transthyretin. NI301A removes ATTR deposits ex vivo from patient-derived myocardium by macrophages, as well as in vivo from mice grafted with patient-derived ATTR fibrils in a dose- and time-dependent fashion. The biological activity of ATTR removal involves antibody-mediated activation of phagocytic immune cells including macrophages. These data support the evaluation of safety and tolerability of NI301A in an ongoing phase 1 clinical trial in patients with ATTR cardiomyopathy.<\/jats:p>","DOI":"10.1038\/s41467-021-23274-x","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T10:02:59Z","timestamp":1621936979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-4881","authenticated-orcid":false,"given":"Aubin","family":"Michalon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hagenbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Huy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-0449","authenticated-orcid":false,"given":"Evita","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Combaluzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-2369","authenticated-orcid":false,"given":"Ole B.","family":"Suhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-6899","authenticated-orcid":false,"given":"Maria J.","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Nitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-3298","authenticated-orcid":false,"family":"Jan Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"23274_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz, M. A. et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J. Am. Coll. Cardiol. 66, 2451\u20132466 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"23274_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/jne.12271","volume":"27","author":"B Alshehri","year":"2015","unstructured":"Alshehri, B., D\u2019Souza, D. G., Lee, J. Y., Petratos, S. & Richardson, S. J. The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption. J. Neuroendocrinol. 27, 303\u2013323 (2015).","journal-title":"J. Neuroendocrinol."},{"key":"23274_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13038-z","volume":"10","author":"M Schmidt","year":"2019","unstructured":"Schmidt, M. et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat. Commun. 10, 5008 (2019).","journal-title":"Nat. Commun."},{"key":"23274_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando, Y. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet. J. Rare Dis. 8, 31 (2013).","journal-title":"Orphanet. J. Rare Dis."},{"key":"23274_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer, M. S. et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J. Am. Coll. Cardiol. 68, 161\u2013172 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"23274_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann. Med. 40, 232\u2013239 (2008).","journal-title":"Ann. Med."},{"key":"23274_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed, S. F. et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2, 113\u2013122 (2014).","journal-title":"JACC Heart Fail."},{"key":"23274_CR8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez, E. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 36, 2585\u20132594 (2015).","journal-title":"Eur. Heart J."},{"key":"23274_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","volume":"32","author":"Y Bennani Smires","year":"2016","unstructured":"Bennani Smires, Y. et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int. J. Cardiovasc. Imaging 32, 1403\u20131413 (2016).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"23274_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","volume":"19","author":"JL Cavalcante","year":"2017","unstructured":"Cavalcante, J. L. et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J. Cardiovasc. Magn. Reson. 19, 98 (2017).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"23274_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","volume":"71","author":"PR Scully","year":"2018","unstructured":"Scully, P. R. et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 71, 463\u2013464 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"23274_CR12","doi-asserted-by":"publisher","first-page":"e01371","DOI":"10.1002\/brb3.1371","volume":"9","author":"MA Gertz","year":"2019","unstructured":"Gertz, M. A., Mauermann, M. L., Grogan, M. & Coelho, T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav. 9, e01371 (2019).","journal-title":"Brain Behav."},{"key":"23274_CR13","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1073\/pnas.96.6.3108","volume":"96","author":"G Goldsteins","year":"1999","unstructured":"Goldsteins, G. et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc. Natl Acad. Sci. USA 96, 3108\u20133113 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"23274_CR14","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.2174\/092986712800269335","volume":"19","author":"SK Palaninathan","year":"2012","unstructured":"Palaninathan, S. K. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr. Med. Chem. 19, 2324\u20132342 (2012).","journal-title":"Curr. Med. Chem."},{"key":"23274_CR15","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1021\/bi952501g","volume":"35","author":"Z Lai","year":"1996","unstructured":"Lai, Z., Col\u00f3n, W. & Kelly, J. W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35, 6470\u20136482 (1996).","journal-title":"Biochemistry"},{"key":"23274_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt, J. W. et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci. Rep. 8, 6412 (2018).","journal-title":"Sci. Rep."},{"key":"23274_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin, K. et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 93\u201397 (2010).","journal-title":"Nature"},{"key":"23274_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro, A. et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J. Am. Coll. Cardiol. 70, 466\u2013477 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"23274_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jcct.2015.07.001","volume":"9","author":"TA Treibel","year":"2015","unstructured":"Treibel, T. A. et al. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J. Cardiovasc. Comput. Tomogr. 9, 585\u2013592 (2015).","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"23274_CR20","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","volume":"3","author":"T Damy","year":"2016","unstructured":"Damy, T. et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart 3, e000289 (2016).","journal-title":"Open Heart"},{"key":"23274_CR21","doi-asserted-by":"publisher","first-page":"e0143456","DOI":"10.1371\/journal.pone.0143456","volume":"10","author":"S Arvidsson","year":"2015","unstructured":"Arvidsson, S., Pilebro, B., Westermark, P., Lindqvist, P. & Suhr, O. B. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis - impact of sex and amyloid fibril composition. PLoS ONE 10, e0143456 (2015).","journal-title":"PLoS ONE"},{"key":"23274_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","volume":"68","author":"AV Kristen","year":"2016","unstructured":"Kristen, A. V. et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J. Am. Coll. Cardiol. 68, 13\u201324 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"23274_CR23","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.bpj.2009.12.4317","volume":"98","author":"Z Xu","year":"2010","unstructured":"Xu, Z., Paparcone, R. & Buehler, M. J. Alzheimer\u2019s abeta(1-40) amyloid fibrils feature size-dependent mechanical properties. Biophys. J. 98, 2053\u20132062 (2010).","journal-title":"Biophys. J."},{"key":"23274_CR24","doi-asserted-by":"publisher","unstructured":"dem Siepen, F. A. et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin. Res. Cardiol. https:\/\/doi.org\/10.1007\/s00392-017-1167-1 (2017).","DOI":"10.1007\/s00392-017-1167-1"},{"key":"23274_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"23274_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"23274_CR27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"23274_CR28","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk, J. L. et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310, 2658\u20132667 (2013).","journal-title":"JAMA"},{"key":"23274_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"23274_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein, G. et al. Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimers Res. Ther. 11, 101 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"23274_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg, S. M. et al. Cerebral amyloid angiopathy and Alzheimer disease \u2014 one peptide, two pathways. Nat. Rev. Neurol. 16, 30\u201342 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"23274_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","volume":"124","author":"A Weihofen","year":"2019","unstructured":"Weihofen, A. et al. Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol. Dis. 124, 276\u2013288 (2019).","journal-title":"Neurobiol. Dis."},{"key":"23274_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ajpath.2017.01.022","volume":"187","author":"CK Nobuhara","year":"2017","unstructured":"Nobuhara, C. K. et al. Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am. J. Pathol. 187, 1399\u20131412 (2017).","journal-title":"Am. J. Pathol."},{"key":"23274_CR34","doi-asserted-by":"publisher","first-page":"eaah3924","DOI":"10.1126\/scitranslmed.aah3924","volume":"10","author":"M Maier","year":"2018","unstructured":"Maier, M. et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci. Transl. Med. 10, eaah3924 (2018).","journal-title":"Sci. Transl. Med."},{"key":"23274_CR35","first-page":"190","volume":"19","author":"MT Elghetany","year":"1989","unstructured":"Elghetany, M. T., Saleem, A. & Barr, K. The Congo red stain revisited. Ann. Clin. Lab. Sci. 19, 190\u2013195 (1989).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"23274_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1172\/JCI105784","volume":"47","author":"M Pras","year":"1968","unstructured":"Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A. & Franklin, E. C. The characterization of soluble amyloid prepared in water. J. Clin. Invest. 47, 924\u2013933 (1968).","journal-title":"J. Clin. Invest."},{"key":"23274_CR37","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","volume":"292","author":"M Lo","year":"2017","unstructured":"Lo, M. et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J. Biol. Chem. 292, 3900\u20133908 (2017).","journal-title":"J. Biol. Chem."},{"key":"23274_CR38","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards, D. B. et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. NEJM.\u00a0373, 1106\u20131114 (2015).\u00a0","journal-title":"NEJM."},{"key":"23274_CR39","doi-asserted-by":"publisher","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","volume":"10","author":"DB Richards","year":"2018","unstructured":"Richards, D. B. et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci. Transl. Med.\u00a010, eaan3128 (2018).\u00a0","journal-title":"Sci. Transl. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23274-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:35:12Z","timestamp":1669984512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23274"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23274-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M., A.H., C. Huy, E.V., B.C., C. Hock, R.M.N. and J.G. are or were (E.V.) employees of Neurimmune. O.B.S. participates in clinical trials for Alnylam and Prothena Pharmaceuticals, and has served in Advisory boards for Pfizer, Alnylam, Akcea, Prothena, and Intellia Pharmaceuticals, and has participated in educational activities sponsored by Alnylam and Akcea Pharmaceuticals. T.D. participates in clinical trials and has served in Advisory boards for Alnylam, Akcea, Pfizer, and Prothena Pharmaceuticals. M.J.S. does not have competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3142"}}